REFERENCES
1. Siegel RL, Kratzer TB, Wagle NS, Sung H, Jemal A. Cancer statistics, 2026. CA Cancer J Clin. 2026;76:e70043.
2. Mohan Lal B, Kumar SK. New approaches for measurable residual disease assessment in multiple myeloma: integrating NGS, mass spectrometry, and next-generation flow cytometry to monitor treatment response. Curr Hematol Malig Rep. 2026;21:4.
3. Park M, Lim DJ, Kim H, et al. Complementary roles of next-generation flow and next-generation sequencing for measurable residual disease assessment in multiple myeloma. J Korean Med Sci. 2026;41:e5.
4. Lin X, Liu B, Wu J, et al. Circulating tumor DNA in breast cancer: from technological foundation to clinical implementation. Cancer Treat Rev. 2026;144:103108.
5. Kahwati LC, Avenarius M, Brouwer L, et al. Multicancer detection tests for screening: a systematic review. Ann Intern Med. 2025;178:1591-604.
6. Schrag D, Beer TM, Mcdonnell CH, et al. Blood-based tests for multicancer early detection (PATHFINDER): a prospective cohort study. Lancet. 2023;402:1251-60.
7. Oliver J, Garcia-Aranda M, Chaves P, et al. Emerging noninvasive methylation biomarkers of cancer prognosis and drug response prediction. Semin Cancer Biol. 2022;83:584-95.
8. Suraweera A, O’byrne KJ, Richard DJ. Epigenetic drugs in cancer therapy. Cancer Metastasis Rev. 2025;44:37.
9. Scandolara TB, Siqueira IVM, Ribeiro Pinto LF, Soares-Lima SC. The power and the promise of epigenetic drugs in oncology. Front Genet. 2026;16:1622115.
10. Barbato MI, Barone AK, Aungst SL, et al. FDA approval summary: vorasidenib for IDH-mutant grade 2 astrocytoma or oligodendroglioma following surgery. Clin Cancer Res. 2025;31:4412-8.
11. Issa GC, Aldoss I, Dipersio J, et al. The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia. Nature. 2023;615:920-4.
13. Chang L, Wang M, Zhang H, et al. Synthesis and clinical application of small-molecule drugs approved by FDA in 2025. Med Res Rev. 2026;46:1543-73.
15. Peña M, Lazzari L, Martínez DF, et al. Treosulfan/fludarabine versus thiotepa/busulfan/fludarabine for allogeneic haematopoietic cell transplantation in lymphoma in the post-transplant cyclophosphamide era: AGETH-TC study. Br J Haematol. 2026;208:1017-26.
16. De Moraes E Sousa E, Luciano MCDS, De Souza GC, et al. Isoflavonoids and epigenetic modulation: therapeutic insights for cancer treatment. Chem Biodiversity. 2026;23:e03446.
17. Wang Y, Xie Q, Tan H, et al. Targeting cancer epigenetic pathways with small-molecule compounds: Therapeutic efficacy and combination therapies. Pharmacol Res. 2021;173:105702.
18. Ashraf W, Ahmad T, Reynoird N, et al. Natural and synthetic anticancer epidrugs targeting the epigenetic integrator UHRF1. Molecules. 2023;28:5997.
19. Khan MA, Tania M, Fu J. Epigenetic role of thymoquinone: impact on cellular mechanism and cancer therapeutics. Drug Discov Today. 2019;24:2315-22.
20. Zhang F, Zhang L, Dong Y, et al. ADAM9 in cancer: a comprehensive analysis of mutation, prognostic value, expression and TQFL12-induced inhibition. J Transl Genet Genom. 2026;10:140-55.
21. Raha P, Thomas S, Thurn KT, Park J, Munster PN. Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression. Breast Cancer Res. 2015;17:26.
22. Szylberg M, Sokal P, Śledzińska P, et al. MGMT promoter methylation as a prognostic factor in primary glioblastoma: a single-institution observational study. Biomedicines. 2022;10:2030.
23. Sperduto PW, De B, Li J, et al. Graded prognostic assessment (GPA) for patients with lung cancer and brain metastases: initial report of the small cell lung cancer GPA and update of the non-small cell lung cancer GPA including the effect of programmed death ligand 1 and other prognostic factors. Int J Radiat Oncol Biol Phys. 2022;114:60-74.
24. Scarpi E, Nanni O, Maltoni M. Development and validation of the PaP score nomogram for terminally Ill cancer patients. Cancers. 2022;14:2510.
25. Chen X, Meng X, Zhang W, et al. Cell-free chromatin state tracing reveals disease origin and therapy responses. Nature. 2026;653:599-610.
26. Tang Z, Yan S, Xu S, et al. Advances in CRISPR-based molecular biosensing: from pathogen detection to early tumor screening. J Transl Genet Genom. 2026;10:343-68.
27. Huang Z, Ma R, Xiao Z, Zhou X. Epigenetic dysregulation of gastrointestinal tumors. J Transl Genet Genom. 2026;10:442-61.
28. Fu JJ, Li LY, Lu GX. Molecular cloning and characterization of human DDX36 and mouse Ddx36 genes, new members of the DEAD/H box superfamily. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao. 2002;34:655-61. Available from: https://pubmed.ncbi.nlm.nih.gov/12198572/ [Last accessed on 13 Oct 2026].
29. Chen MC, Tippana R, Demeshkina NA, et al. Structural basis of G-quadruplex unfolding by the DEAH/RHA helicase DHX36. Nature. 2018;558:465-9.
30. Wei C, Xu D, Cheng J, et al. DHX36 plays an oncogenic role in breast cancer progression and invasiveness. Sci Rep. 2025;16:1156.
31. El-Far A, Cheng J, Fu L, et al. Decoding the DHX36-m6A-G4 axis: exploring its role in health and disease through epigenetic and molecular insights. J Transl Genet Genom. 2026;10:89-118.
32. Zhang Y, Zhao J, Chen X, et al. DHX36 binding induces RNA structurome remodeling and regulates RNA abundance via m6A reader YTHDF1. Nat Commun. 2024;15:9890.
